A Phase 1 interventional study of Cholecalciferol D3 and Placebo tablet in Asthma, sponsored by Copenhagen Studies on Asthma in Childhood. Active, not recruiting at 2 sites in Denmark. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-19.
Sponsored by Copenhagen Studies on Asthma in Childhood · Phase 1, Interventional, and Prevention
The aim of this study is to prevent asthma symptoms (recurrent wheeze) in childhood by supplementation with high dose vitamin D to the mother during pregnancy. Participants are mothers and children of the ABC (Asthma Begins in Childhood) cohort. Mothers are recruited during pregnancy and receive daily supplement with 2400 IU of Vitamin D3 or placebo from week 24 og gestation to 1 week after delivery. In addition all mothers are advised to take the recommended dose of 400 IU vitamin D daily. The mothers in ABC also participate in an interventional trial with fish oil supplementation, and the vitamin D randomization is stratified by fish oil treatment group. The child is followed with acute and planned vits at the research unit, and wheeze is diagnosed according to predefined algorithms.
3,921 studies on the registry are indexed under Asthma; 507 are open to participants now.
This study's planned enrollment of 600 is above the median of 83 across 2,752 interventional studies indexed under Asthma.
Browse Asthma studies →Copenhagen Studies on Asthma in Childhood is the lead sponsor of 8 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Mother:
Exclusion Criteria:
Mother:
Dietary supplement: 2400 IU Vitamin D3 (2 tablets of 1200 IU) from week 24 of gestation to 1 week after delivery
Dietary Supplement: Cholecalciferol D3
Placebo: 2 placebo tablets with no active substance, identical to the active tablets, from week 24 of gestation to 1 week after delivery
Other: Placebo tablet
2 tablets of 1200 IU daily from week 24 of gestation to 1 week after delivery
Also known as: Vitamin D from Camette, Denmark
2 tablets containing no active substance
Also known as: Placebo tablets from Camette, Denmark
Persistent wheeze
Age at onset of persistent wheeze diagnosed according to predefined algorithm of recurrent troublesome lung symptoms, response to treatment and relapse after withdrawal of treatment
Time frame: 0 to 3 years of age
Infections
Main analysis: • Number of lower respiratory tract infections registered in daily diaries Secondary analyses: * Acute otitis media * Number of upper respiratory tract infections * Number of other infections * Total number of infections
Time frame: 0 to 3 years of age
Allergic sensitization
Allergic sensitization at 6 and/or 18 months assessed by skin prick test and specific IgE in blood
Time frame: 6 and 18 months of age
Eczema
Age at onset of eczema diagnosed prospectively by research doctors according to predefined algorithm based upon Hanifin and Rajka criteria
Time frame: 0 to 3 years of age
Mothers levels of 25-OH-Vitamin D, PTH, Calcium, alkaline phosphatase
Time frame: 1 week after delivery
Growth
Time frame: 0 to 3 years of age
Asthma exacerbations
Age at onset of severe asthma exacerbation diagnosed by predefined criteria of acute severe asthma requiring oral/high dose inhaled steroids or acute hospital contact
Time frame: 0 to 3 years of age
Neurological development
Main analysis: • Cognitive development assessed at 2½ years using the cognitive part of Bayley Scales of Infant and Toddler Development, third edition Secondary analyses: * Milestone development monitored prospectively by the parents using a registration form based on The Denver Development Index and WHO milestones registration (combined assessment by principal component analysis) * Language development assessed at 1 and 2 years of age with the Danish version of The MacArthur Bates Communicative Developmental Inventory (CDI) * The child´s general development (language, fine and gross motor, social and problem solving) at 3 years of age assessed with Ages and stages Questioner, third edition (ASQ-3)
Time frame: 0-3 years
Growth
Main analysis: • Body composition (fat mass and bone mineral density) assessed by DEXA scan at 3 years of age Secondary analysis • Development of BMI from birth to 3 years assesses longitudinally in the research clinic
Time frame: 0-3 years
Systemic immune status
Main analysis Immune status at 18 months measured in stimulated whole blood as cytokine release (combined assessments by prinicipal component analyses) Secondary analyses Composition of immune cell subsets in whole blood at birth and at 18 months of age
Time frame: 18 months
Airway mucosal immune status
Immune status measured in airway mucosal lining fluid at 4 weeks and 2 years of age (combined assessments by prinicipal component analyses for each age point)
Time frame: 4 weeks and 2 years
17q21 genotype and sphingolipid metabolites
In a secondary analyses, we will determine the effect of 17q21 genotype on the efficacy of vitamin D supplementation in the prevention of asthma/wheeze. We will compute hazard ratios for the reduction in asthma/wheeze risk associated with prenatal supplementation, stratified by rs12936231. rs12936231 is a functional SNP influencing expression of ORMDL3, and given the role of ORMDL3 as a key sphingolipid biosynthesis regulator, we will subsequently investigate the relative abundance of sphingolipids between those in the vitamin D Intervention arm and those in the placebo group, stratified by 17q21 genotype. Finally we will identify interactions between prenatal vitamin D supplementation, rs12936231 genotype and sphingolipid metabolism in the risk of asthma/wheeze by age three.
Time frame: 6 months
Dental health
Caries and enamel defects (molar incisor hypomineralization, MIH) determined at a dental examination at age 6 years.
Time frame: 6 year
Asthma
Asthma diagnosed from age 3 to 10 years based on the same predefined algorithm of recurrent troublesome lung symptoms, response to treatment after withdrawal of treatment, which was used for persistent wheeze at age 0-3 in phase 1 of the study. Primary outcome in phase 2 is current asthma at specific visits till age 10 years, which is diagnosed in children fulfilling the persistent wheeze algorithm at any point during the first 10 years of life and still needing inhaled corticosteroids at specific visits (3, 4, 5, 6, 8 and 10 years of age) to control the symptoms.
Time frame: 3-10 years of age
Lung function measurements
Spirometry measuring airflow assessed by FEV1, MMEF and FEV1/FVC ratio at age 5, 6, 8 and 10 years.
Time frame: 5-10 years of age
Infections
Prescribed medicine for infections. Types and length of infections
Time frame: 3-10 years of age
Growth
Anthropometrics: Clinical follow up on the development of weight in kg (calibrated digital weight scales), height in cm (Harpenden stadiometer), waist-, thorax- and head circumference in cm (using tape; 3 times each) at every visit till age 10 years assessed longitudinally in the research clinic.
Time frame: 3- 10 years of age
Eczema
Age at onset of eczema diagnosed prospectively by research doctors according to predefined algorithm based upon Hanifin and Rajka criteria
Time frame: 3-10 years of age
Allergic sensitization/atopy
Allergic sensitization at 6 and 10 years of age assessed by skin prick test (ALK-Abelló, Denmark) and specific IgE in blood (ImmunoCAP, PHarmacia Diagnostics AB, Sweden).
Time frame: 6-10 years of age
Airway mucosal immune status
Immune status measured in airway mucosal lining fluid at 3, 6 and 10 years of age (combined assessments by principal component analyses for each age point).
Time frame: 3-10 years of age
The diagnose allergic rhinitis
Allergic rhinitis will be diagnosed by combining allergic sensitization with symptom recording of troublesome congestion or sneezing or runny nose upon relevant exposure to allergens at age 3, 4, 5, 6, 8 and 10 years.
Time frame: 3-10 years of age
Asthma exacerbations:
Age at onset and number of severe asthma exacerbation diagnosed by predefined criteria of acute severe asthma requiring oral/ high dose inhaled steroids or acute hospital contact
Time frame: 3-10 years of age
Airway resistance
Measured by plethysmography (sRaw) at age 3, 4, 5, 6, 8 and 10 years.
Time frame: 3-10 years of age
Airway resistance
Multiple breath wash-out using SF6 and N2 as inert gasses to determined LCI, Scond and Sacin at ages 3, 4 and 5 years.
Time frame: 3-5 years of age
Bronchial reactivity:
Provocative dose of methacholine leading to a 20% drop in FEV1 from baseline (PD20 value) at age 6 years.
Time frame: at 6 years of age
Body composition
Body composition measured as fat mass, lean mass, bone mineral content (BMC) and bone mineral density assessed (BMD) through DXA scans at 3, 6 and 13 years of age. Body impedance measurements at 10 years of age.
Time frame: 3-13 years of age
Airway inflammation:
Measurement of fractional exhaled nitric oxide (FeNO) at age 6, 8 and 10 years
Time frame: 6-10 years of age
Cognitive function
A 2,5 hours cognitive evaluation at 10 years of age. Cognitive functions from a broad spectrum of cognitive domains will be assessed with subtests both using paper pencil tests and Cambridge Neuropsychological Test Automated Battery .
Time frame: 10 years of age
MRI scanning of the Brain
MRI scanning of the Brain
Time frame: 10 years of age
Behavioral and psychopathological dimensions.
Questionnaires will be administered to the parents.
Time frame: 6- 10 years of age
Behavioral and psychopathological dimensions.
Behavioral and psychopathological dimensions will be assessed at 10 years of age. The childrens' potential psychiatric diagnoses will be ascertained through the semi-structured clinical interview Schedule for Affective Disorders and Schizophrenia for School-Age Children - Present and Lifetime Version (K-SADS-PL) first with a parent and next with the child.
Time frame: 10 years of age
Strength and Difficulties Questionnaire (SDQ)- Questionnaires
The Strengths and Difficulties Questionnaire (SDQ) is a brief behavioural screening questionnaire about 3-16 year olds. Questionnaires will be administered to the parents to obtain their evaluation of their child's potential psychopathology and behavior problems. Scores will be calculated form the questionnaires in order validated methods
Time frame: 6, 8 and 10 years of age
ADHD- RS- Questionnaires
The ADHD Rating Scale obtains parent ratings regarding the frequency of each ADHD symptom based on DSM criteria. Questionnaires will be administered to the parents to obtain their evaluation of their child's potential psychopathology and behavior problems. Scores will be calculated form the questionnaires. Scores will be calculated form the questionnaires in order validated methods.
Time frame: 8 and 10 years of age
Social Responsive Scale, Second version (SRS-2)
The SRS-2 identifies social impairment associated with autism spectrum disorders (ASDs) and quantifies its severity Questionnaires will be administered to the parents to obtain their evaluation of their child's potential psychopathology. Scores will be calculated form the questionnaires. Scores will be calculated form the questionnaires in order validated methods.
Time frame: 10 years of age
The Child Behavior Checklist school-age version (CBCL)
The Child Behavior Checklist (CBCL) is a widely used questionnaire to assess behavioral and emotional problems. Questionnaires will be administered to the parents to obtain their evaluation of their child's potential psychopathology and behavior problems. Scores will be calculated form the questionnaires. Scores will be calculated form the questionnaires in order validated methods.
Time frame: 10 years of age
The Behavior Rating Inventory of Executive Function 2nd edition (BRIEF-2)
The BRIEF-2 is a set of questionnaires for parents and teachers , designed to evaluate executive function from multiple perspectives. Questionnaires will be administered to the parents to obtain their evaluation of their child's potential psychopathology. Scores will be calculated form the questionnaires. Scores will be calculated form the questionnaires in order validated methods.
Time frame: 10 years of age
Bone fractures
Description: Assessed by medical record checks including all radiologically verified fractures of larger long bones (i.e. clavicle, radius, ulna, tibia, fibula, femur and humerus). Outcome analyses: total no. of fractures age 0-13 years.
Time frame: 0-13 years of age
This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Copenhagen Studies on Asthma in Childhood